Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (29)
Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda, Yoshiaki Nagai, Takayuki Kishikawa, Ken Masubuchi, Takashi Osaki, Yosuke Miura, Yukihiro Umeda, Akihiro Ono, Hiroyuki Minemura, Yutaka Yamada, Junichi Nakagawa, Yuki Kozu, Hirokazu Taniguchi, Hiromitsu Ohta, Takashi Kasai, Kyoichi Kaira & Hiroshi Kagamu. (2023) Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed. Thoracic Cancer.
Crossref
Crossref
Katsunori Tanaka, Hitoshi Hirakawa, Mikio Suzuki, Teruyuki Higa, Shinya Agena, Narumi Hasegawa, Junko Kawakami, Masatomo Toyama, Tomoyo Higa, Hidetoshi Kinjyo, Norimoto Kise, Shunsuke Kondo, Hiroyuki Maeda & Taro Ikegami. (2023) Biomarkers for Predicting Anti-Programmed Cell Death-1 Antibody Treatment Effects in Head and Neck Cancer. Current Oncology 30:6, pages 5409-5424.
Crossref
Crossref
Yohei Asano, Norio Yamamoto, Satoru Demura, Katsuhiro Hayashi, Akihiko Takeuchi, Satoshi Kato, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi, Yuta Taniguchi, Sei Morinaga, Takashi Sone, Miho Okuda, Isao Matsumoto, Seiji Yano & Hiroyuki Tsuchiya. (2023) Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis. Cancer Medicine 12:11, pages 12425-12437.
Crossref
Crossref
Menglu Dai & Wei Wu. (2023) Prognostic role of C-reactive protein to albumin ratio in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Frontiers in Oncology 13.
Crossref
Crossref
Rocío Jiménez Galán, Elena Prado-Mel, Maria Alvarez de Sotomayor & Laila Abdel-Kader Martin. (2023) Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. Biology 12:2, pages 191.
Crossref
Crossref
Jinghua Yang, Yaping Wan, Qianxi Ni, Jianhong Zuo, Jin Wang, Xiapeng Zhang & Lifang Zhou. (2022) Quantifying causal effects from observed data using quasi-intervention. BMC Medical Informatics and Decision Making 22:1.
Crossref
Crossref
Yusheng Guo, Dongqiao Xiang, Jiayu Wan, Lian Yang & Chuansheng Zheng. (2022) Focus on the Dynamics of Neutrophil-to-Lymphocyte Ratio in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-Analysis and Systematic Review. Cancers 14:21, pages 5297.
Crossref
Crossref
Elena Bolzacchini, Monica Giordano, Lorenza Bertù, Marco Bregni, Olga Nigro, Luca Galli, Andrea Antonuzzo, Salvatore Artale, Sabrina Barzaghi, Marco Danova, Martina Torchio, Graziella Pinotti & Francesco Dentali. (2021) Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib. Tumori Journal 108:5, pages 502-509.
Crossref
Crossref
Qing Wu, Shuimei Luo & Xianhe Xie. (2022) Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. Journal of Immunotherapy 45:7, pages 307-320.
Crossref
Crossref
Yongchao Zhang, Bozhi Liu, Sergei Kotenko & Wei Li. (2022) Prognostic value of neutrophil-lymphocyte ratio and lactate dehydrogenase in melanoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Medicine 101:32, pages e29536.
Crossref
Crossref
Yukinori Takenaka, Ryohei Oya, Norihiko Takemoto & Hidenori Inohara. (2022) Neutrophil‐to‐lymphocyte ratio as a prognostic marker for head and neck squamous cell carcinoma treated with immune checkpoint inhibitors: Meta‐analysis. Head & Neck 44:5, pages 1237-1245.
Crossref
Crossref
Yoon-Koo Kang, Satoshi Morita, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Hiroki Sameshima, Li-Tzong Chen & Narikazu Boku. (2021) Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study. Gastric Cancer 25:1, pages 207-217.
Crossref
Crossref
D. Viñal, L. Gutierrez-Sainz, D. Martinez, J. A. Garcia-Cuesta, J. Pedregosa, J. Villamayor, L. Ostios, D. Sanchez-Cabrero, O. Higuera, A. Pinto, N. Rodriguez-Salas, E. Espinosa, J. de Castro & J. Feliu. (2020) Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. Clinical and Translational Oncology 23:6, pages 1185-1192.
Crossref
Crossref
Edoardo Lenci, Giulia Marcantognini, Valeria Cognigni, Alessio Lupi, Silvia Rinaldi, Luca Cantini, Ilaria Fiordoliva, Anna Lisa Carloni, Marco Rocchi, Lina Zuccatosta, Stefano Gasparini & Rossana Berardi. (2021) Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis. Exploration of Targeted Anti-tumor Therapy.
Crossref
Crossref
Qing Wu, Junjin Liu, Sumei Wu & Xianhe Xie. (2021) The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts. International Immunopharmacology 92, pages 107303.
Crossref
Crossref
Rangarirai Makuku, Neda Khalili, Sepideh Razi, Mahsa Keshavarz-Fathi & Nima Rezaei. (2021) Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. Journal of Immunology Research 2021, pages 1-15.
Crossref
Crossref
Cristina Valero, Mark Lee, Douglas Hoen, Kate Weiss, Daniel W. Kelly, Prasad S. Adusumilli, Paul K. Paik, George Plitas, Marc Ladanyi, Michael A. Postow, Charlotte E. Ariyan, Alexander N. Shoushtari, Vinod P. Balachandran, A. Ari Hakimi, Aimee M. Crago, Kara C. Long Roche, J. Joshua Smith, Ian Ganly, Richard J. Wong, Snehal G. Patel, Jatin P. Shah, Nancy Y. Lee, Nadeem Riaz, Jingming Wang, Ahmet Zehir, Michael F. Berger, Timothy A. Chan, Venkatraman E. Seshan & Luc G. T. Morris. (2021) Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nature Communications 12:1.
Crossref
Crossref
Amy S Codd, Stephanie J Hanna, Ewoud B Compeer, Felix C Richter, Eleanor J Pring, Ester Gea-Mallorquí, Mariana Borsa, Owen R Moon, D Oliver Scourfield, David J Ahern, Hannah Almuttaqi, Dominic S Alonzi, Aljawharah Alrubayyi, Ghada Alsaleh, Valentina M T Bart, Vicky Batchelor, Rebecca Bayliss, Dorothée L Berthold, Jelena S Bezbradica, Tehmina Bharuchq, Helene Borrmann, Mariana Borsa, Rowie Borst, Juliane Brun, Stephanie Burnell, Lorenzo Capitani, Athena Cavounidis, Lucy Chapman, Anne Chauveau, Liliana Cifuentes, Amy Susan Codd, Ewoud Bernardus Compeer, Clarissa Coveney, Amy Cross, Sara Danielli, Luke C Davies, Calliope A Dendrou, Sandra Dimonte, Ruban Rex Peter Durairaj, Lynn B Dustin, Arthur Dyer, Ceri Fielding, Fabian Fischer, Awen Gallimore, Sarah Galloway, Anís Gammage, Ester Gea-Mallorquí, Andrew Godkin, Stephanie Jean Hanna, Cornelia Heuberger, Sarah Hulin-Curtis, Fadi Issa, Emma Jones, Ruth Jones, Kristin Ladell, Sarah N Lauder, Kate Liddiard, Petros Ligoxygakis, Fangfang Lu, Bruce MacLachlan, Shayda Maleki-Toyserkani, Elizabeth H Mann, Anna M Marzeda, Reginald James Matthews, Julie M Mazet, Anita Milicic, Emma Mitchell, Owen Moon, Van Dien Nguyen, Miriam O'Hanlon, Clara Eléonore Pavillet, Dimitra Peppa, Ana Pires, Eleanor Pring, Max Quastel, Sophie Reed, Jan Rehwinkel, Niamh Richmond, Felix Clemens Richter, Alice J B Robinson, Patrícia R S Rodrigues, Pragati Sabberwal, Arvind Sami, Raphael Sanches Peres, Quentin Sattentau, Barbora Schonfeldova, David Oliver Scourfield, Tharini A Selvakumar, Freya R Shepherd, Cariad Shorten, Anna Katharina Simon, Adrian L Smith, Alicia Teijeira Crespo, Michael Tellier, Emily Thornton, Lion F K Uhl, Erinke van Grinsven, Angus K T Wann, Richard Williams, Joseph D Wilson, Dingxi Zhou, Zihan Zhu, Awen M Gallimore & Anita Milicic. (2021) Neutrophilia, lymphopenia and myeloid dysfunction: a living review of the quantitative changes to innate and adaptive immune cells which define COVID-19 pathology. Oxford Open Immunology 2:1.
Crossref
Crossref
Ratika Srivastava. 2021. Skin Cancer: Pathogenesis and Diagnosis. Skin Cancer: Pathogenesis and Diagnosis
21
40
.
Meghan A. Cupp, Margarita Cariolou, Ioanna Tzoulaki, Dagfinn Aune, Evangelos Evangelou & Antonio J. Berlanga-Taylor. (2020) Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Medicine 18:1.
Crossref
Crossref
M. Bonomi, P. Bhateja, M. Issa, B. Klamer, X. Pan, A. Blakaj, V. Karivedu, L. Mousa, D. Mitchell, M Gamez, S. Kang, Nolan B. Seim, M. Old, R. Carrau, J. Rocco & D. Blakaj. (2020) A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors. Oral Oncology 110, pages 104900.
Crossref
Crossref
Mutlu Hizal, Mehmet AN Sendur, Hatime Arzu Yasar, Kadriye Bir Yucel, Cagatay Arslan, Gokhan Ucar, Serdar Karakaya, Hakan Taban, Ahmet Kucukarda, Ismail Erturk, Burak Bilgin, Nuriye Yıldırım, Umut Demirci, Saadettin Kılıckap, Irfan Cicin, Nuri Karadurmus, Bulent Yalcin & Yüksel Ürün. (2020) Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). Journal of Oncology Pharmacy Practice 26:7, pages 1583-1589.
Crossref
Crossref
Katarzyna Tomela, Bernadeta Pietrzak, Marcin Schmidt & Andrzej Mackiewicz. (2020) The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. Life 10:10, pages 219.
Crossref
Crossref
Sebastien Jaillon, Andrea Ponzetta, Diletta Di Mitri, Angela Santoni, Raffaella Bonecchi & Alberto Mantovani. (2020) Neutrophil diversity and plasticity in tumour progression and therapy. Nature Reviews Cancer 20:9, pages 485-503.
Crossref
Crossref
Na Zhang, Jianjun Jiang, Sihui Tang & Gengyun Sun. (2020) Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. International Immunopharmacology 85, pages 106677.
Crossref
Crossref
Vera Petrova, Ihor Arkhypov, Rebekka Weber, Christopher Groth, Peter Altevogt, Jochen Utikal & Viktor Umansky. (2020) Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. International Journal of Molecular Sciences 21:7, pages 2367.
Crossref
Crossref
Junyu Long, Jianzhen Lin & Haitao Zhao. (2020) Application of the Lung Immune Prognostic Index From Research to Clinical Practice. JAMA Oncology 6:2, pages 299.
Crossref
Crossref
Vera Petrova, Ihor Arkhypov, Rebekka Weber, Christopher Groth, Peter Altevogt, Jochen Utikal & Viktor Umansky. (2020) Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom. Kompass Dermatologie 8:3, pages 92-101.
Crossref
Crossref
Ying Huang & Aizong Shen. (2020) The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients. Medicine 99:34, pages e21718.
Crossref
Crossref